←
Roche14,841 posts
Roche avatar✓

Roche ✓

@Roche

We advance science so that we all have more time with the people we love. Read our community guidelines: go.roche.com/CG

◷ Joined February 2009▧ 6,281 Photos and videos
Roche avatar
Roche@Roche·Oct 3

Roche’s Women as Visionaries in Eyecare (#WAVE) initiative connects women in ophthalmology whose work, experience and ambition are helping shape eyecare. If you’re at #EURETINA2026, join us at the Roche booth for inspiring talks and to connect with a community working to move the field forward. #EURETINA26

Post attachment
Roche avatar
Roche@Roche·Oct 2

HR-positive #BreastCancer is the most common subtype, but early-stage recurrence and progression following initial therapies remain a reality for many. Together, we’re working to help change this.

Roche avatar
Roche@Roche·Oct 2

We continue to focus our scientific efforts on areas of high unmet need, aiming to translate research insights into meaningful health solutions.

Roche avatar
Roche@Roche·Oct 2

Timely insight is critical in oncology. Advanced diagnostic approaches allow healthcare teams to better understand disease complexity and support informed clinical decisions.

Roche avatar
Roche@Roche·Oct 2

At Roche our commitment to #BreastCancer research has been guided by science and a dedication to improving outcomes for people living with cancer. 🧵👇

Roche avatar
Roche@Roche·Oct 2

To move retinal care forward, we must understand how solutions perform in everyday practice. As @EURETINA 2026 continues, Nilesh Mehta, Therapeutic Area Head, Ophthalmology at Roche, is sharing what our latest real-world evidence could mean for patients with neovascular age-related macular degeneration (#nAMD) and diabetic macular edema (#DME). #EURETINA26

Post attachment
Roche avatar
Roche@Roche·Oct 1

#MEDIA – We are pleased that the New England Journal of Medicine has published phase III data demonstrating significant progression-free survival benefit with our investigational medicine for people with ER-positive advanced #BreastCancer. Read more here👉spkl.io/60117pcYh $ROG $RHHBY

Post attachment
Roche avatar
Roche@Roche·Oct 1

Expanding the possible starts with fresh ideas, emerging leaders and new perspectives. The Leading Edge Incubator (LEI) is designed to empower the next generation shaping the future of ophthalmology. Attending #EURETINA26? Stop by the Roche booth to meet current LEI members and learn about innovations from the 2025-26 cohort. #EURETINA2026

Post attachment
Roche avatar
Roche@Roche·Oct 1

#MEDIA – At #EURETINA2026, we’re pleased to share new real-world data confirming effectiveness and safety across major retinal conditions, including nAMD, DME and RVO.

Post attachment
Roche avatar
Roche@Roche·Sep 25

Better cancer outcomes shouldn't demand bigger budgets—they demand smarter innovation. Reflecting on this year's World Cancer Congress, the path forward is clear: the real cost of cancer isn’t just treatment, but the time stolen from families when care comes too late. By prioritising earlier diagnosis and care closer to home, we don't just free up hospital capacity. We change the equation entirely—turning progress into healthy years of life. #WhatsItWorth #WCC2026 #GlobalHealth

Post attachment
Roche avatar
Roche@Roche·Sep 24

Breast cancer care shouldn't depend on where you live. At this year's World Cancer Congress, the message was clear: regional collaboration is key to ensuring every woman gets the care she deserves, no matter where she lives. By working across borders to bring diagnosis and treatment closer to home, we can turn progress into time—time for women to keep pursuing their dreams. #WhatsItWorth #WCC2026 #GlobalHealth

Post attachment
Roche avatar
Roche@Roche·Sep 23

#MEDIA – We are excited to share positive interim phase III results in IgA nephropathy, a progressive kidney disease that can lead to kidney failure. Read more here 👉 spkl.io/60157TnLZ $ROG $RHHBY

Post attachment
Roche avatar
Roche@Roche·Sep 22

We are pleased to share positive topline Phase II results from our investigational dual GLP-1/GIP receptor agonist in people living with type 2 diabetes, obesity or overweight. Read more here: spkl.io/60197Tn6V $ROG $RHHBY #Obesity

Post attachment
Roche avatar
Roche@Roche·Sep 21

#MEDIA - We are pleased to share that the European Commission (EC) has approved our continuous delivery treatment for adults with neovascular age-related macular degeneration (#nAMD), offering an alternative to standard-of-care eye injections. roche.com/media

Post attachment